Skip to main content
SpringerLink
Log in

Talimogene laherparepvec increases risk of skin disorders in patients receiving ICIs

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Increased risk of cutaneous immune-related adverse events in patients treated with talimogene laherparepvec and immune checkpoint inhibitors: A multi-hospital cohort study Journal of the American Academy of Dermatology : 21 Mar 2023. Available from: URL: https://doi.org/10.1016/j.jaad.2023.02.017

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Talimogene laherparepvec increases risk of skin disorders in patients receiving ICIs. Reactions Weekly 1950, 12 (2023). https://doi.org/10.1007/s40278-023-36409-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-023-36409-0

Search

Navigation